kininogen-1 O-glycosylated 40 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-532 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G58001LT. Example: UniProtKB:P01042-1, Thr-532, MOD:00005~GNO:G58001LT.


kininogen-1 isoform LMW (human)

A kininogen-1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P01042-2.


kininogen-1 N-glycosylated 13 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-205 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G08293MJ. Example: UniProtKB:P01042-1, Asn-205, MOD:00160~GNO:G08293MJ.


kininogen-1 N-glycosylated 14 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-205 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G17015OC. Example: UniProtKB:P01042-1, Asn-205, MOD:00160~GNO:G17015OC.


kininogen-1 O-glycosylated 28 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-273 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:P01042-1, Thr-273, MOD:00005~GNO:G29068FM.


kininogen-1 N-glycosylated 3 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-169 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G11115RO. Example: UniProtKB:P01042-1, Asn-169, MOD:00160~GNO:G11115RO.


kininogen-1 O-glycosylated 25 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-151 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G17015OC. Example: UniProtKB:P01042-1, Thr-151, MOD:00005~GNO:G17015OC.


kininogen-1 N-glycosylated 24 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-294 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G08293MJ. Example: UniProtKB:P01042-1, Asn-294, MOD:00160~GNO:G08293MJ.


kininogen-1 O-glycosylated 18 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-137 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:P01042-1, Thr-137, MOD:00005~GNO:G29068FM.


kininogen-1 O-glycosylated 9 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Ser-550 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P01042-1, Ser-550, MOD:00002~GNO:G43417UB.


kininogen-1 O-glycosylated 45 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-542 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:P01042-1, Thr-542, MOD:00005~GNO:G53434XO.


kininogen-1 O-glycosylated 17 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-137 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G23729WG. Example: UniProtKB:P01042-1, Thr-137, MOD:00005~GNO:G23729WG.


kininogen-1 O-glycosylated 46 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-546 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:P01042-1, Thr-546, MOD:00005~GNO:G29068FM.


kininogen-1 O-glycosylated 15 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Ser-604 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P01042-1, Ser-604, MOD:00002~GNO:G43417UB.


kininogen-1 isoform HMW (human)

A kininogen-1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P01042-1.


name: kininogen-1, signal peptide removed phosphorylated form (human)

description: A kininogen-1 (human) that has had the signal peptide removed and that includes at least 1 phosphorylated residue. Example: UniProtKB:P01042-1, 19-644, MOD:00696.


kininogen-1 O-glycosylated 1 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Ser-120 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:P01042-1, Ser-120, MOD:00002~GNO:G53434XO.


kininogen-1 O-glycosylated 35 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-401 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G58001LT. Example: UniProtKB:P01042-1, Thr-401, MOD:00005~GNO:G58001LT.


kininogen-1 N-glycosylated 17 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-205 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G59626AS. Example: UniProtKB:P01042-1, Asn-205, MOD:00160~GNO:G59626AS.


kininogen-1 N-glycosylated 6 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-169 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G59626AS. Example: UniProtKB:P01042-1, Asn-169, MOD:00160~GNO:G59626AS.


kininogen-1 O-glycosylated 7 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Ser-408 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P01042-1, Ser-408, MOD:00002~GNO:G43417UB.


kininogen-1 O-glycosylated 26 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-151 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:P01042-1, Thr-151, MOD:00005~GNO:G29068FM.


kininogen-1 O-glycosylated 39 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-532 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:P01042-1, Thr-532, MOD:00005~GNO:G53434XO.


kininogen-1 N-glycosylated 10 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-169 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G99679NM. Example: UniProtKB:P01042-1, Asn-169, MOD:00160~GNO:G99679NM.


kininogen-1 N-glycosylated 32 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-294 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G59626AS. Example: UniProtKB:P01042-1, Asn-294, MOD:00160~GNO:G59626AS.


kininogen-1 N-glycosylated 2 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-169 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G06247RL. Example: UniProtKB:P01042-1, Asn-169, MOD:00160~GNO:G06247RL.


kininogen-1 N-glycosylated 26 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-294 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G27947YN. Example: UniProtKB:P01042-1, Asn-294, MOD:00160~GNO:G27947YN.


kininogen-1 O-glycosylated 49 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-571 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G23729WG. Example: UniProtKB:P01042-1, Thr-571, MOD:00005~GNO:G23729WG.


kininogen-1 N-glycosylated 15 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-205 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G27947YN. Example: UniProtKB:P01042-1, Asn-205, MOD:00160~GNO:G27947YN.


kininogen-1 O-glycosylated 21 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-137 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G57317CE. Example: UniProtKB:P01042-1, Thr-137, MOD:00005~GNO:G57317CE.


kininogen-1 O-glycosylated 13 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Ser-604 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G23729WG. Example: UniProtKB:P01042-1, Ser-604, MOD:00002~GNO:G23729WG.


kininogen-1 N-glycosylated 23 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-294 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G06247RL. Example: UniProtKB:P01042-1, Asn-294, MOD:00160~GNO:G06247RL.


kininogen-1 O-glycosylated 38 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-532 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P01042-1, Thr-532, MOD:00005~GNO:G43417UB.


kininogen-1 N-glycosylated 8 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-169 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G94917XT. Example: UniProtKB:P01042-1, Asn-169, MOD:00160~GNO:G94917XT.


kininogen-1 O-glycosylated 20 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-137 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:P01042-1, Thr-137, MOD:00005~GNO:G53434XO.


kininogen-1 O-glycosylated 47 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-546 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P01042-1, Thr-546, MOD:00005~GNO:G43417UB.


kininogen-1 O-glycosylated 19 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-137 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P01042-1, Thr-137, MOD:00005~GNO:G43417UB.


kininogen-1 O-glycosylated 41 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-533 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:P01042-1, Thr-533, MOD:00005~GNO:G29068FM.


kininogen-1 O-glycosylated 24 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-137 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G95678HJ. Example: UniProtKB:P01042-1, Thr-137, MOD:00005~GNO:G95678HJ.


kininogen-1 O-glycosylated 37 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-407 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:P01042-1, Thr-407, MOD:00005~GNO:G53434XO.


kininogen-1 O-glycosylated 32 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-401 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G06247RL. Example: UniProtKB:P01042-1, Thr-401, MOD:00005~GNO:G06247RL.


kininogen-1 N-glycosylated 5 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-169 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:P01042-1, Asn-169, MOD:00160~GNO:G29068FM.


kininogen-1 O-glycosylated 3 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Ser-150 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G27947YN. Example: UniProtKB:P01042-1, Ser-150, MOD:00002~GNO:G27947YN.


kininogen-1 O-glycosylated 11 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Ser-599 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P01042-1, Ser-599, MOD:00002~GNO:G43417UB.


kininogen-1 O-glycosylated 14 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Ser-604 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:P01042-1, Ser-604, MOD:00002~GNO:G29068FM.


kininogen-1 N-glycosylated 21 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-205 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G94917XT. Example: UniProtKB:P01042-1, Asn-205, MOD:00160~GNO:G94917XT.


name: kininogen-1, signal peptide removed form (human)

description: A kininogen-1 (human) that has had the signal peptide removed. UniProtKB:P01042, 19-644.


kininogen-1 O-glycosylated 34 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-401 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:P01042-1, Thr-401, MOD:00005~GNO:G53434XO.


kininogen-1 N-glycosylated 25 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-294 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G10486CT. Example: UniProtKB:P01042-1, Asn-294, MOD:00160~GNO:G10486CT.


kininogen-1 N-glycosylated 18 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-205 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G85144OK. Example: UniProtKB:P01042-1, Asn-205, MOD:00160~GNO:G85144OK.


kininogen-1 N-glycosylated 36 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-48 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G06247RL. Example: UniProtKB:P01042-1, Asn-48, MOD:00160~GNO:G06247RL.


kininogen-1 N-glycosylated 7 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-169 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G85144OK. Example: UniProtKB:P01042-1, Asn-169, MOD:00160~GNO:G85144OK.


kininogen-1 N-glycosylated 35 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-48 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G00912UN. Example: UniProtKB:P01042-1, Asn-48, MOD:00160~GNO:G00912UN.


kininogen-1 N-glycosylated 9 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-169 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G95678HJ. Example: UniProtKB:P01042-1, Asn-169, MOD:00160~GNO:G95678HJ.


kininogen-1 O-glycosylated 23 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-137 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G94917XT. Example: UniProtKB:P01042-1, Thr-137, MOD:00005~GNO:G94917XT.


kininogen-1 O-glycosylated 12 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Ser-599 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:P01042-1, Ser-599, MOD:00002~GNO:G53434XO.


kininogen-1 N-glycosylated 33 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-294 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G85144OK. Example: UniProtKB:P01042-1, Asn-294, MOD:00160~GNO:G85144OK.


kininogen-1 N-glycosylated 31 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-294 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G58001LT. Example: UniProtKB:P01042-1, Asn-294, MOD:00160~GNO:G58001LT.


kininogen-1 O-glycosylated 42 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-533 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P01042-1, Thr-533, MOD:00005~GNO:G43417UB.


kininogen-1 N-glycosylated 22 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-294 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G00912UN. Example: UniProtKB:P01042-1, Asn-294, MOD:00160~GNO:G00912UN.


kininogen-1 N-glycosylated 19 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-205 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G86752LQ. Example: UniProtKB:P01042-1, Asn-205, MOD:00160~GNO:G86752LQ.


kininogen-1 N-glycosylated 20 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-205 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G88374WZ. Example: UniProtKB:P01042-1, Asn-205, MOD:00160~GNO:G88374WZ.


kininogen-1 O-glycosylated 4 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Ser-150 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P01042-1, Ser-150, MOD:00002~GNO:G43417UB.


kininogen-1 N-glycosylated 28 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-294 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G40926MX. Example: UniProtKB:P01042-1, Asn-294, MOD:00160~GNO:G40926MX.


kininogen-1 N-glycosylated 34 (human)

A kininogen-1 (human) that has been N-glycosylated at the residue equivalent to Asn-294 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G94917XT. Example: UniProtKB:P01042-1, Asn-294, MOD:00160~GNO:G94917XT.


name: neuromedin-K receptor phosphorylated 1 (human)

description: A neuromedin-K receptor (human) that has been phosphorylated on the residue at the position equivalent to Tyr-256 of the amino acid sequence represented by UniProtKB:P29371. UniProtKB:P29371, Tyr-256, MOD:00048.


name: versican core protein, signal peptide removed form (human)

description: A versican core protein (human) that has had the signal peptide removed. UniProtKB:P13611, 21-3396.


name: phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN sequence variant C124Y (human)

description: A phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (human) that has a Tyr residue at the position equivalent to Cys-124 of the amino acid sequence represented by UniProtKB:P60484-1. Example: UniProtKB:P60484-1, Cys-124, CHEBI:46858.


name: parathyroid hormone/parathyroid hormone-related peptide receptor

description: A parathyroid hormone receptor that is a translation product of the human PTH1R gene or a 1:1 ortholog thereof.


parathyroid hormone receptor

A secretin-like G-protein coupled receptor that is a translation product of the human PTH1R or PTH2R genes, 1:1 orthologs thereof, or a semi-ortholog thereof.


parathyroid hormone 2 receptor

A parathyroid hormone receptor that is a translation product of the human PTH2R gene or a 1:1 ortholog thereof.


name: parathyroid hormone 2 receptor phosphorylated 1 (human)

description: A parathyroid hormone 2 receptor (human) that has been phosphorylated on the residue at the position equivalent to Ser-212 of the amino acid sequence represented by UniProtKB:P49190. UniProtKB:P49190, Ser-212, MOD:00046.


name: parathyroid hormone 2 receptor, signal peptide removed form (human)

description: A parathyroid hormone 2 receptor (human) that has had the signal peptide removed. UniProtKB:P49190, 25-550.


name: parathyroid hormone/parathyroid hormone-related peptide receptor, signal peptide removed form (human)

description: A parathyroid hormone/parathyroid hormone-related peptide receptor (human) that has had the signal peptide removed. UniProtKB:Q03431, 27-593.


A53 Diffuse Large B-Cell Lymphoma

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A genetic subtype of diffuse large B-cell lymphoma characterized by TP53 gene mutations and deletions that is often accompanied by aneuploidy.


Unresectable NUT Carcinoma

description: NUT carcinoma that is not amenable to surgical resection.


name: signal recognition particle subunit SRP72

description: A protein that is a translation product of the human SRP72 gene or a 1:1 ortholog thereof.


name: signal recognition particle subunit SRP72 phosphorylated 1 (human)

description: A signal recognition particle subunit SRP72 (human) that has been phosphorylated on the residue at the position equivalent to Thr-28 of the amino acid sequence represented by UniProtKB:O76094-1. Example: UniProtKB:O76094-1, Thr-28, MOD:00047.


name: signal recognition particle subunit SRP72 deaminated 1 (human)

description: A signal recognition particle subunit SRP72 (human) that has been deaminated on the residue at the position equivalent to Gln-107 of the amino acid sequence represented by UniProtKB:O76094-1. Example: UniProtKB:O76094-1, Gln-107, MOD:00685.


name: signal recognition particle subunit SRP72 isoform h1 (human)

description: A signal recognition particle subunit SRP72 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O76094-1.


name: signal recognition particle subunit SRP72 isoform h2 (human)

description: A signal recognition particle subunit SRP72 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O76094-2.


name: signal recognition particle subunit SRP72 methylated 1 (human)

description: A signal recognition particle subunit SRP72 (human) that has been methylated on the residue at the position equivalent to Cys-323 of the amino acid sequence represented by UniProtKB:O76094-1. Example: UniProtKB:O76094-1, Cys-323, MOD:00660.


spindle cell nevus

description: A nevus characterized by the presence of spindle-shaped melanocytes.


name: DNA mismatch repair protein Msh6 methylated 1 (human)

description: A DNA mismatch repair protein Msh6 (human) that has been methylated on the residue at the position equivalent to Cys-1241 of the amino acid sequence represented by UniProtKB:P52701-1. Example: UniProtKB:P52701-1, Cys-1241, MOD:00660.


name: Childhood Recurrent Malignant Solid Neoplasm

description: The reemergence of a childhood malignant solid neoplasm after a period of remission.


amelogenesis imperfecta type 2A1

description: Any amelogenesis imperfecta in which the cause of the disease is a mutation in the KLK4 gene.


name: receptor-type tyrosine-protein kinase FLT3 sequence variant D839G, signal peptide removed form (human)

description: A receptor-type tyrosine-protein kinase FLT3 (human) that has a Gly residue at the position equivalent to Asp-839 of the amino acid sequence represented by UniProtKB:P36888-1 and that has had the signal peptide removed. Example: UniProtKB:P36888-1, 27-993, Asp-839, CHEBI:29947.


name: adhesion G-protein coupled receptor D1 isoform h1 (human)

description: An adhesion G-protein coupled receptor D1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6QNK2-1.


name: transcription factor E4F1 methylated 2 (human)

description: A transcription factor E4F1 (human) that has been methylated on the residue at the position equivalent to Cys-225 of the amino acid sequence represented by UniProtKB:Q66K89. UniProtKB:Q66K89, Cys-225, MOD:00660.


Pelvic Floor Muscle Weakness

description: A reduction in the strength of the muscles of the pelvic floor.


name: lysophospholipase D GDPD3 isoform h1 (human)

description: A lysophospholipase D GDPD3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q7L5L3-2.


specific developmental disorder

description: A developmental disorder of mental health that categorizes specific learning disabilities and developmental disorders affecting coordination.


communication disorder

description: A disorder characterized by an individual's inability to comprehend or share ideas or feelings because of an impairment in language, speech, or hearing.


name: attention deficit-hyperactivity disorder 8


specific language impairment

description: A language disorder characterized by difficulty in language acquisition despite otherwise normal development and in the absence of any obvious explanatory factors.


name: mixed receptive-expressive language disorder

description: A disorder characterized by an impairment in the development of an individual's expressive and receptive language capabilities which is in contrast to his/her nonverbal intellect. The impairment may be acquired (i.e., due to a brain lesion or head trauma) or developmental (i.e., no known neurological insult).


articulation disorder

description: A disorder characterized by the failure to use developmentally expected speech sounds that are appropriate for the individual's age (i.e., the individual makes errors in sound production or use or omits sounds such as final consonants).


specific language impairment 5

description: A communication disorder that involves the processing of linguistic information.


fetal nicotine spectrum disorder

description: A specific developmental disorder that is characterized by physical, behavioral and learning birth defects resulting from maternal ingestion of nicotine during pregnancy.


writing disorder

description: A learning disability that involves impaired written language ability such as impairments in handwriting, spelling, organization of ideas, and composition.


expressive language disorder

description: A disorder characterized by an impairment in the development of an individual's expressive language which is in contrast to his/her nonverbal intellect and receptive language development. The impairment may be acquired (i.e., due to a brain lesion or head trauma) or developmental (i.e., no known neurological insult).


name: hereditary attention deficit-hyperactivity disorder

description: An instance of attention deficit-hyperactivity disorder that is caused by an inherited genomic modification in an individual.


name: neurobehavioral disorder with prenatal alcohol exposure

description: A fetal alcohol spectrum disorder that is characterized by one or more deficits in neurocognition and in self-regulation plus two or more deficits in adaptive functioning, with at least 1 in communication or social communication and interaction.


SAVININ

A lignan that is dihydrofuran-2(3H)-one (gamma-butyrolactone) substituted by a 1,3-benzodioxol-5-ylmethylidene group at position 3 and a 1,3-benzodioxol-5-ylmethyl group at position 4 (the 3E,4R-isomer). It exhibits antiviral activity against SARS-CoV-2.


roundabout homolog 1 isoform h1 (human)

A roundabout homolog 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9Y6N7-1.


name: procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 deaminated 1 (human)

description: A procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (human) that has been deaminated on the residue at the position equivalent to Asn-725 of the amino acid sequence represented by UniProtKB:O00469-1. Example: UniProtKB:O00469-1, Asn-725, MOD:00684.


name: high affinity immunoglobulin gamma Fc receptor I isoform h2 (human)

description: A high affinity immunoglobulin gamma Fc receptor I (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P12314-2.


name: Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor with Seminoma

description: A malignant germ cell tumor arising from the testis.  It is characterized by a mixture of embryonal carcinoma, yolk sac, and seminomatous morphologic elements.  Patients may present with painless or painful testicular swelling.


name: cytochrome c, initiator methionine removed N6-acetyllysine form (human)

description: A cytochrome c (human) that has had the initiator methionine removed and that includes at least 1 N6-acetyllysine. UniProtKB:P99999, 2-105, MOD:00064.


name: Refractory Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma

description: Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma that is resistant to treatment.


name: Stage III Childhood Non-Hodgkin Lymphoma by Toronto Guidelines v2

description: Tumors (extranodal) or nodal areas on both sides (above and below) of the diaphragm or any primary intrathoracic tumors (mediastinal, hilar, pulmonary, pleural, or thymic) or extensive (unresectable) primary intra-abdominal disease or any paraspinal or epidural tumors regardless of other tumor sites. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Lugano Classification Advanced Stage Adult Non-Hodgkin Lymphoma AJCC v8

description: Advanced stage adult non-Hodgkin lymphoma based on the Lugano classification criteria. It includes stages III and IV. (from AJCC 8th Ed.)


Advanced Non-Hodgkin Lymphoma

description: Non-Hodgkin lymphoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Stage I Diffuse Large B-Cell Lymphoma

description: Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


name: Helicobacter Pylori-Associated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

description: A low grade, indolent B-cell lymphoma that is associated with Helicobacter pylori infection.


Intestinal T-cell lymphoma recurrent

description: The reemergence of enteropathy-associated T-cell lymphoma after a period of remission.


name: Adult T-Cell Leukemia/Lymphoma by Ann Arbor Stage

description: An anatomic stage for adult T-cell leukemia/lymphoma based on the Ann Arbor classification criteria.


name: Mycosis Fungoides and Sezary Syndrome by AJCC v7 Stage

description: A term that refers to the staging of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v7 classification system.


name: Primary Cutaneous B-Cell Non-Hodgkin Lymphoma

description: A B-cell non-Hodgkin lymphoma arising from the skin.  Representative examples include cutaneous marginal zone B-cell lymphoma and cutaneous follicle center lymphoma.


name: Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

description: EBV-positive diffuse large B-cell lymphoma, not otherwise specified that is resistant to treatment.


name: Central Nervous System Anaplastic Large Cell Lymphoma, ALK-Negative

description: An anaplastic large cell lymphoma, ALK-negative, arising from the central nervous system.


name: Stage IV Childhood Lymphoblastic Lymphoma

description: Stage IV: Tumors involve bone marrow and/or central nervous system (CNS) regardless of other sites of involvement (from PDQ).


name: Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8

description: Stage IVA1 includes: T1-4, N0-2, M0, B2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)


Adult Burkitt Lymphoma

description: A Burkitt lymphoma occurring in adults.


Advanced Follicular Lymphoma

description: Follicular lymphoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Recurrent Transformed Mycosis Fungoides

description: The reemergence of transformed mycosis fungoides after a period of remission.


Grade 1 Cutaneous Follicular Lymphoma

description: A cutaneous lymphoma which contains up to 5 centroblasts per 40X high-power microscopic field.


name: Recurrent Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation

description: The reemergence of diffuse large B-cell lymphoma associated with chronic inflammation after a period of remission.


name: Primary mediastinal large B-cell lymphoma stage IV

description: Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Centroblastic lymphoma stage II

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE). The number of regions involved may be indicated by a subscript (e.g., II3).


name: Recurrent Breast Implant-Associated Anaplastic Large Cell Lymphoma

description: The reemergence of breast implant-associated anaplastic large cell lymphoma after a period of remission.


Primary Cutaneous Non-Hodgkin Lymphoma

description: A B-or T-cell non-Hodgkin lymphoma arising in the skin.


name: Lugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8

description: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)


name: Lung Intravascular Large B-Cell Lymphoma

description: An aggressive extranodal B-cell non-Hodgkin lymphoma that affects the lung.  It is characterized by the presence of large neoplastic lymphocytes exclusively in the lumina of small vessels, particularly capillaries.


Transformed Mycosis Fungoides

description: Histologic transformation of mycosis fungoides to an aggressive non-Hodgkin lymphoma.


Adult Lymphoblastic Lymphoma

description: A lymphoblastic lymphoma occurring in adults.


name: Mycosis fungoides/Sezary syndrome stage I

description: Stage I includes: IA (T1, N0, M0, B0-1); IB (T2, N0, M0, B0-1). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface.  May further stratify into T1a (patch only) vs. T1b (plaque +/- patch).  T2: Patches, papules, or plaques covering 10% or more of the skin surface.  May further stratify into T2a (patch only) vs. T2b (plaque +/- patch).  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)


name: Ann Arbor Stage II Subdiaphragmatic Nodular Lymphocyte Predominant B-Cell Lymphoma


name: Refractory High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements

description: High-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements that is resistant to treatment.


name: Ann Arbor Stage IV Grade 2 Follicular Lymphoma


grade 3A follicular lymphoma

description: A grade 3 follicular lymphoma in which centrocytes are present.


Refractory Grade 1 Follicular Lymphoma

description: Grade 1 follicular lymphoma that is resistant to treatment.


name: Refractory Primary Vitreoretinal Non-Hodgkin Lymphoma

description: Primary vitreoretinal non-Hodgkin lymphoma that does not respond to treatment.


Recurrent Adult Immunoblastic Lymphoma

description: The reemergence of adult immunoblastic lymphoma after a period of remission.


name: Follicle center lymphoma, follicular grade I, II, III stage IV


name: Childhood Primary Cutaneous Anaplastic Large Cell Lymphoma

description: An anaplastic large cell lymphoma that occurs during childhood and is limited to the skin at the time of diagnosis.


Follicular lymphoma stage I

description: Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


name: Colorectal High Grade B-Cell Lymphoma, Not Otherwise Specified

description: High-grade B-cell lymphoma, not otherwise specified, that arises from the colorectal region.


description: Lymphoplasmacytic lymphoma resistant to treatment.


Indolent T-Cell Non-Hodgkin Lymphoma

description: A T-cell non-Hodgkin lymphoma with an indolent clinical course.


name: Precursor B-lymphoblastic lymphoma stage II

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


non-Hodgkin's lymphoma of spleen

description: Non-Hodgkin lymphoma involving the spleen.


name: Primary Ciliary Body Non-Hodgkin Lymphoma

description: An extremely rare low-grade B-cell non-Hodgkin lymphoma that arises from the ciliary body. It is characterized by the presence of a diffuse infiltrate of small, round lymphocytes. Most cases represent extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue.


name: Mantle Cell Lymphoma with CCND3 Rearrangement

description: Mantle cell lymphoma characterized by the presence of CCND3 gene rearrangement. A small number of cases express this gene rearrangement and not CCND1 gene rearrangement.


name: Ann Arbor Stage II Grade 3 Follicular Lymphoma


name: Cutaneous Nasal Type Extranodal NK/T-Cell Lymphoma

description: Nasal type extranodal NK/T-cell lymphoma affecting the skin.


name: Head and Neck Large B-Cell Lymphoma with IRF4 Rearrangement

description: A large B-cell lymphoma with IRF4 rearrangement that arises from the head and neck region, usually the Waldeyer ring and/or cervical lymph nodes.


name: Methotrexate-Associated Diffuse Large B-Cell Lymphoma

description: A diffuse large B-cell lymphoma that develops in patients who are immunosuppressed with methotrexate.


name: Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7

description: Stage IIIA includes: T4, N0-2, M0, B0.  T4: Confluence of erythema covering 80% or more of body surface area.  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  (AJCC 7th ed.)


name: Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma

description: The reemergence of primary cutaneous anaplastic large cell lymphoma after a period of remission.


Tonsillar Diffuse Large B-Cell Lymphoma

description: Diffuse large B-cell lymphoma that affects the tonsil and the bulk of the tumor is in this anatomic area.


name: Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7

description: Stage IVA includes: IVA1 (T1-4, N0-2, M0, B2); IVA2 (T1-4, N3, M0, B0-2). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface.  May further stratify into T1a (patch only) vs. T1b (plaque +/- patch).  T2: Patches, papules, or plaques covering 10% or more of the skin surface.  May further stratify into T2a (patch only) vs. T2b (plaque +/- patch).  T3: One or more tumors (equal or greater than 1 cm diameter).  T4: Confluence of erythema covering 80% or more of body surface area.  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  B2: High blood tumor burden: 1000/microL Sezary cells or more with positive clone.  (AJCC 7th ed.)


Burkitt's lymphoma refractory

description: Burkitt lymphoma that is resistant to treatment.


Extranodal Non-Hodgkin Lymphoma

description: A non-Hodgkin lymphoma that arises from an anatomic site other than a lymph node.


Mycosis fungoides/Sezary syndrome

description: Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome.


name: Localized Anaplastic Large Cell Lymphoma

description: Anaplastic large cell lymphoma that is confined to a specific site without evidence of spread to other anatomic sites.


name: Conjunctival Diffuse Large B-Cell Lymphoma

description: A diffuse large B-cell lymphoma that arises from the conjunctiva.


name: B-Cell Non-Hodgkin Lymphoma by Ann Arbor Stage

description: An anatomic stage for B-cell non-Hodgkin lymphoma based on the Ann Arbor classification criteria.


name: non-Hodgkin's lymphoma of accessory sinus

description: A non-Hodgkin lymphoma that arises from the paranasal sinus.  Representative examples include diffuse large B-cell lymphoma and extranodal NK/T-cell lymphoma, nasal type.


Cecum Non-Hodgkin Lymphoma

description: An extranodal non-Hodgkin lymphoma that arises from the cecum.  The majority are B-cell non-Hodgkin lymphomas.


Cutaneous Follicular Lymphoma

description: A follicular lymphoma involving the skin.  A cutaneous follicular lymphoma may be metastatic to the skin from the lymph nodes or other anatomic sites or primary (cutaneous follicle center lymphoma).


name: Stage III Childhood Non-Hodgkin Lymphoma

description: Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


name: systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood

description: Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoproliferative disease of childhood is a rare and very aggressive neoplastic disease emerging after a primary acute or chronic active EBV infection. It presents with persisting fever and malaise, hepatosplenomegaly with or without lymphadenopathy, liver failure, severe pancytopenia and a rapid progression towards multi-organ failure and hemophagocytic syndrome with a fatal issue. It is characterized by clonal proliferation of EBV-infected T cells with an activated cytotoxic phenotype.


Systemic Anaplastic Large Cell Lymphoma

description: An anaplastic large cell lymphoma that is not confined to a single anatomic site and involves multiple nodal and/or extranodal sites.


name: High Grade B-Cell Lymphoma with MYC and BCL6 Rearrangements

description: High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC and BCL6 genes.


name: Head and Neck Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

description: An extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue that affects the head and neck region. It usually arises from the ocular adnexa and salivary glands.


name: Lacrimal System Diffuse Large B-Cell Lymphoma

description: A diffuse large B-cell lymphoma that arises from the lacrimal gland or the lacrimal drainage system.


name: Primary mediastinal large B-cell lymphoma recurrent

description: The reemergence of primary mediastinal large B-cell lymphoma after a period of remission.


Stage II Adult Burkitt Lymphoma

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Marginal zone lymphoma recurrent

description: The reemergence of marginal zone lymphoma after a period of remission.


name: Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma

description: Ann Arbor Stage II diffuse large B-cell lymphoma with a mass of nodes with one diameter more than 10cm or a mediastinal mass larger than one third of the transthoracic width. (Cotswolds modification)


name: Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

description: Histologic transformation of a marginal zone lymphoma to an aggressive diffuse large B-cell lymphoma.


name: Cutaneous Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type

description: Follicular helper T-cell lymphoma, angioimmunoblastic-type affecting the skin.


Diffuse follicle center lymphoma

description: A lymphoma with the morphologic and immunophenotypic features of a follicular lymphoma characterized by the presence of a diffuse growth pattern with only focal and usually small micronodular foci.


Stage I Adult Immunoblastic Lymphoma

description: Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


Intestinal T-cell lymphoma refractory

description: Enteropathy-associated T-cell lymphoma that is resistant to treatment.


name: Colorectal Mucosa-Associated Lymphoid Tissue Lymphoma

description: An extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue that arises from the colon or rectum.


name: Childhood EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

description: An EBV-positive diffuse large B-cell lymphoma, not otherwise specified, that occurs during childhood. It was originally described in patients older than 50 years, but it has been increasingly recognized in younger patients.


name: Ann Arbor Stage II Non-Contiguous Adult Non-Hodgkin Lymphoma

description: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (from PDQ)


name: Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

description: An aggressive B-cell non-Hodgkin lymphoma that is resistant to treatment.


name: Recurrent Aggressive T-Cell Non-Hodgkin Lymphoma

description: The reemergence of an aggressive T-cell non-Hodgkin lymphoma after a period of remission.


name: Primary Vitreoretinal Diffuse Large B-Cell Lymphoma

description: An uncommon and potentially fatal diffuse large B-cell lymphoma that involves the uvea, retina, vitreous body, and optic nerve. It is a subset of primary central nervous system diffuse large B-cell lymphoma.


Stage II Non-Hodgkin Lymphoma

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE). The number of regions involved may be indicated by a subscript (e.g., II3).


name: Primary cutaneous diffuse large cell B-cell lymphoma

description: A diffuse large B-cell lymphoma that arises from the skin. This category includes primary cutaneous diffuse large B-cell lymphoma, leg type, and primary cutaneous diffuse large B-cell lymphoma, other, which includes primary cutaneous intravascular large B-cell lymphoma and primary cutaneous T-cell/histiocyte-rich large B-cell lymphoma.


name: B-cell small lymphocytic lymphoma stage I


mantle cell lymphoma of small intestine

description: A mantle cell lymphoma that arises from the small intestine.  It may present as an isolated mass in the small intestine or as a part of the multiple lymphomatous polyposis.


Refractory T Lymphoblastic Lymphoma

description: T-lymphoblastic lymphoma that does not respond to treatment.


name: High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements

description: High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC and BCL2 genes.


name: Recurrent Grade III Lymphomatoid Granulomatosis


name: Childhood Systemic Anaplastic Large Cell Lymphoma

description: A systemic anaplastic large cell lymphoma that occurs during childhood.


Pituitary Gland Non-Hodgkin Lymphoma

description: A rare non-Hodgkin lymphoma that arises from the pituitary gland. The majority are diffuse large B-cell lymphomas.


Parotid Gland Follicular Lymphoma

description: A follicular lymphoma that manifests initially in the parotid gland.


name: Recurrent ALK-Positive Large B-Cell Lymphoma

description: The reemergence of ALK-positive large B-cell lymphoma after a period of remission.


name: Childhood Non-Hodgkin Lymphoma by Toronto Guidelines v2 Stage, Tier 2

description: A term that refers to the staging of childhood non-Hodgkin lymphoma according to the tier 2 Toronto childhood cancer staging guidelines v2.


High grade B-cell lymphoma refractory

description: High-grade B-cell lymphoma that is resistant to treatment.


name: Systemic Anaplastic Large Cell Lymphoma, ALK-Negative

description: Anaplastic large cell lymphoma, ALK-negative affecting multiple anatomic sites.


Burkitt lymphoma associated with AIDS

description: A Burkitt lymphoma occurring in HIV-positive patients.


MCD diffuse large B-cell lymphoma

description: A diffuse large B-cell lymphoma that is categorized as MCD with high probability by the LymphGen algorithm. This is based on a combination of genetic features and MCD DLBCLs often, but do not always, have the most common hot spot mutation in MYD88 (L265P) and/or activating mutations in CD79B. This subgroup also commonly has mutations due to aberrant somatic hypermutation affecting PIM1 and/or ETV6, which can be coding or non-coding.


name: Childhood Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

description: A mature T- and NK-cell non-Hodgkin lymphoma that occurs during childhood.


name: Stage IV Childhood Anaplastic Large Cell Lymphoma

description: Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Chronic Adult T-Cell Leukemia/Lymphoma

description: An adult T-cell leukemia/ lymphoma associated with skin lesions and mild lymphadenopathy.  Neoplastic lymphocytes are not numerous in the peripheral blood.  Hypercalcemia is absent.


name: Splenic marginal zone lymphoma recurrent

description: The reemergence of splenic marginal zone lymphoma after a period of remission.


Mycosis fungoides stage III

description: Stage III includes: (T4, N0-2, M0, B0-1); IIIA (T4, N0-2, M0, B0); IIIB (T4, N0-2, M0, B1). T4: Confluence of erythema covering 80% or more of body surface area.  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)


name: Central Nervous System Intravascular Large B-Cell Lymphoma

description: A rare extranodal B-cell non-Hodgkin lymphoma that affects the central nervous system.  It is characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.


name: Ann Arbor Stage II Non-Contiguous Adult Lymphoblastic Lymphoma

description: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (from PDQ)


name: Early Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

description: Primary cutaneous T-cell non-Hodgkin lymphoma that has spread from its original site of growth to nearby tissues.


name: Lymphoplasmacytoid lymphoma/immunocytoma stage I

description: Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


name: Stage II Childhood Lymphoblastic Lymphoma

description: Stage II: Disease extent is limited to a single tumor with regional node involvement, 2 or more tumors or nodal areas involved on one side of the diaphragm, or a primary gastrointestinal tract tumor (completely resected) with or without regional node involvement (from PDQ).


Stage III Adult Immunoblastic Lymphoma

description: Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


name: central nervous system non-hodgkin lymphoma

description: A non-Hodgkin lymphoma that arises from the central nervous system.


name: Recurrent Indolent Adult Non-Hodgkin Lymphoma

description: The reemergence of indolent non-Hodgkin lymphoma in adults after a period of remission.


name: adult nasal type extranodal NK/T-cell lymphoma

description: Nasal type extranodal NK/T-cell lymphoma that occurs in adulthood.


Splenic B Lymphoblastic Lymphoma

description: B-lymphoblastic lymphoma that involves the spleen.


name: Follicular Helper T-Cell Lymphoma, Not Otherwise Specified

description: Follicular helper T-cell lymphoma that does not meet the criteria for any other specifically defined entity of follicular helper T-cell lymphoma.


T-cell lymphoma refractory

description: T-cell non-Hodgkin lymphoma that is resistant to treatment.


name: Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

description: Primary cutaneous T-cell non-Hodgkin lymphoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Transformed Lymphoplasmacytic Lymphoma to Diffuse Large B-Cell Lymphoma

description: Histologic transformation of a lymphoplasmacytic lymphoma to an aggressive diffuse large B-cell lymphoma.


B-cell lymphoma refractory

description: B-cell non-Hodgkin lymphoma that is resistant to treatment.


name: Ann Arbor Stage I Childhood Non-Hodgkin Lymphoma


name: Ann Arbor Stage II Contiguous Mantle Cell Lymphoma

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Recurrent Grade 3b Follicular Lymphoma

description: The reemergence of grade 3b follicular lymphoma after a period of remission.


name: Stage II Non-Contiguous Adult Indolent Non-Hodgkin Lymphoma


name: Childhood Non-Hodgkin Lymphoma by Toronto Guidelines v2 Stage, Tier 1

description: A term that refers to the staging of childhood non-Hodgkin lymphoma according to the tier 1 Toronto childhood cancer staging guidelines v2.


name: Extranodal marginal zone B-cell lymphoma (MALT type) stage IV

description: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue presenting as stage IV disease.


AIDS-Related Lymphoblastic Lymphoma

description: A lymphoblastic lymphoma occurring in HIV-positive patients.


granulomatous slack skin disease

description: Granulomatous slack skin (GSS) is a variant of mycosis fungoides (MF), a form of cutaneous T-cell lymphoma, and is characterized by the presence of circumscribed areas of pendulous lax skin.


EBV-Related Non-Hodgkin Lymphoma

description: Non-Hodgkin lymphoma that is caused by Epstein-Barr virus infection.


Stage I Anaplastic Large Cell Lymphoma

description: Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


Splenic Lymphoblastic Lymphoma

description: Lymphoblastic lymphoma that affects the spleen.


name: Head and Neck Pediatric-Type Follicular Lymphoma

description: A pediatric-type follicular lymphoma that affects the head and neck region.


Centroblastic lymphoma refractory

description: Centroblastic lymphoma, resistant to treatment.


name: Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7

description: Stage III includes: (T4, N0-2, M0, B0-1); IIIA (T4, N0-2, M0, B0); IIIB (T4, N0-2, M0, B1). T4: Confluence of erythema covering 80% or more of body surface area.  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)


Recurrent Immunoblastic Lymphoma

description: The reemergence of immunoblastic lymphoma after a period of remission.


name: Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8

description: Stage IIIB includes: T4, N0-2, M0, B1. T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)


EBV-Negative Burkitt Lymphoma

description: Burkitt lymphoma that is not associated with Epstein-Barr virus infection.


Leukemic Nonnodal Mantle Cell Lymphoma

description: Mantle cell lymphoma involving the peripheral blood, bone marrow, and often spleen. It usually has an indolent clinical course.


Aggressive Adult Non-Hodgkin Lymphoma

description: An aggressive non-Hodgkin lymphoma occurring in adults.  Representative examples include Burkitt lymphoma, precursor B-lymphoblastic lymphoma, precursor T-lymphoblastic lymphoma, and adult T-cell lymphoma/leukemia.


Recurrent Adult Burkitt Lymphoma

description: The reemergence of adult Burkitt lymphoma after a period of remission.


Advanced Diffuse Large B-Cell Lymphoma

description: Diffuse large B-cell lymphoma that has spread extensively to distant anatomic sites or is no longer responding to treatment.


name: Refractory Indolent T-Cell Non-Hodgkin Lymphoma

description: Indolent T-cell non-Hodgkin lymphoma that is resistant to treatment.


name: Refractory Indolent Non-Hodgkin Lymphoma

description: Indolent non-Hodgkin lymphoma that is resistant to treatment.


name: Mycosis Fungoides and Sezary Syndrome by AJCC v8 Stage

description: A term that refers to the staging of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system. This prognostic stage groups system is based on the ISCL/EORTC revision to the staging of mycosis fungoides and Sezary syndrome. There is no prognostic stage groups system for primary cutaneous B-cell/T-cell (non-mycosis fungoides/Sezary syndrome) lymphomas at this time. This staging system does not apply to eyelid skin lymphomas (are staged according to the classification for ocular adnexal lymphoma).  (from AJCC 8th Ed.)


name: Refractory Transformed B-Cell Non-Hodgkin Lymphoma

description: An indolent B-cell non-Hodgkin lymphoma which has undergone histologic transformation to an aggressive B-cell non-Hodgkin lymphoma and has become resistant to treatment.


name: Bladder Mucosa-Associated Lymphoid Tissue Lymphoma

description: A rare mucosa-associated lymphoid tissue lymphoma affecting the bladder.


name: Primary mediastinal large B-cell lymphoma refractory

description: Primary mediastinal large B-cell lymphoma that is resistant to treatment.


description: Burkitt lymphoma in a patient with immunodeficiency.


Recurrent Grade 2 Follicular Lymphoma

description: The reemergence of grade 2 follicular lymphoma after a period of remission.


B-cell lymphoma stage IV

description: Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


name: Stage IA Mycosis Fungoides and Sezary Syndrome AJCC v8

description: Stage IA includes: T1, N0, M0, B0,1. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)


name: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified by Gene Expression Profile

description: A header term that includes the following diffuse large B-cell lymphoma subtypes by gene expression profiling: activated B-cell-like diffuse large B-cell lymphoma, germinal center B-cell-like diffuse large B-cell lymphoma, and type 3 diffuse large B-cell lymphoma.


name: Recurrent Childhood Grade III Lymphomatoid Granulomatosis

description: The reemergence of grade III lymphomatoid granulomatosis in childhood after a period of remission.


name: Refractory Intravascular Large B-Cell Lymphoma

description: Intravascular large B-cell lymphoma that is resistant to treatment.


name: Ann Arbor Stage IV Grade 1 Follicular Lymphoma


Pleural Primary Effusion Lymphoma

description: Primary effusion lymphoma that affects the pleural cavity. The majority of patients are HIV-positive men.


Favorable Non-Hodgkin Lymphoma

description: A non-Hodgkin lymphoma with favorable prognosis.


name: Advanced Stage Childhood Non-Hodgkin Lymphoma by Toronto Guidelines v2

description: Involvement of CNS and/or bone marrow. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma

description: Primary cutaneous diffuse large B-cell lymphoma that is resistant to treatment.


name: Ann Arbor Stage II Non-Contiguous Adult Burkitt Lymphoma

description: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (from PDQ)


name: Salivary Gland Mucosa-Associated Lymphoid Tissue Lymphoma

description: A low-grade extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue arising from a salivary gland. It usually occurs in the parotid gland and is often associated with Sjogren syndrome. The prognosis is favorable.


name: Ann Arbor Stage I Grade 3 Follicular Lymphoma

description: Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


name: Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma

description: The reemergence of subcutaneous panniculitis-like T-cell lymphoma after a period of remission.


name: Ann Arbor Stage II Nodular Lymphocyte Predominant B-Cell Lymphoma

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Pediatric nodal marginal zone lymphoma

description: A nodal marginal zone lymphoma affecting the pediatric population, predominantly males.  It presents with asymptomatic and localized (mainly head and neck) disease in the vast majority of cases.  Morphologically there is often progressive transformation of the germinal centers.  The prognosis is excellent.


name: Refractory NK-Cell Lymphoma, Unclassifiable

description: NK-cell lymphoma, unclassifiable that is resistant to treatment.


name: Refractory Follicular Helper T-Cell Lymphoma, Follicular-Type

description: Follicular helper T-cell lymphoma, follicular-type that is resistant to treatment.


Pancreatic Non-Hodgkin Lymphoma

description: A non-Hodgkin lymphoma that arises from the pancreas with the bulk of the tumor localized to this organ.  The vast majority of cases are of B-cell phenotype and include mucosa-associated lymphoid tissue lymphomas, follicular lymphomas, and diffuse large B-cell lymphomas.


name: Precursor B-lymphoblastic lymphoma stage IV

description: Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Body Cavity Primary Effusion Lymphoma

description: A large B-cell lymphoma presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. (WHO 2017)


Stage II Adult Immunoblastic Lymphoma

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE). The number of regions involved may be indicated by a subscript (e.g., II3).


Stage IA Mycosis Fungoides AJCC v7

description: Stage IA includes: T1, N0, M0, B0-1.  T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface.  May further stratify into T1a (patch only) vs. T1b (plaque +/- patch).  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)


name: Small Intestinal T-Cell Non-Hodgkin Lymphoma

description: A T-cell non-Hodgkin lymphoma that arises from the small intestine.  It includes the enteropathy-associated T-cell lymphoma and the monomorphic CD56 positive intestinal T-cell lymphoma.


name: Stage II Contiguous Adult Indolent Non-Hodgkin Lymphoma


Angiocentric lymphoma refractory

description: Nasal type extranodal NK/T-cell lymphoma that does not respond to treatment.


AIDS-Related Plasmablastic Lymphoma

description: A plasmablastic lymphoma in a patient with acquired immunodeficiency syndrome.


name: High Grade B-Cell Lymphoma, Not Otherwise Specified

description: High-grade B-cell lymphoma with blastoid features or features between diffuse large B-cell lymphoma and Burkitt lymphoma that lacks MYC, BCL2, and BCL6 gene rearrangements.


Pediatric follicular lymphoma

description: A nodal follicular lymphoma with favorable prognosis. It lacks BCL-2 rearrangement and 14;18 translocation. Nearly all cases are localized. It is usually seen in the pediatric population but similar lymphomas may occur in adults.


Sinonasal Extranodal NK/T-Cell Lymphoma

description: An extranodal NK/T-cell lymphoma that arises from the sinonasal tract.


large B-cell diffuse lymphoma of kidney

description: A diffuse large B-cell lymphoma that affects the kidney.


name: Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder

description: A diffuse large B-cell lymphoma that arises in a patient with a history of organ transplantation.


Lymphoma, Mixed-Cell, Follicular

description: A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.


EZB diffuse large B-cell lymphoma

description: A diffuse large B-cell lymphoma that is categorized as EZB with high probability by the LymphGen algorithm. This is based on a combination of genetic features and EZB DLBCLs often, but do not always, have hot spot mutations in EZH2 and/or a BCL2 translocation. This class can be further subdivided into two sub-classes EZB-MYC+ and EZB-MYC- using the double hit gene expression signature (DHITsig). This subgroup also commonly has mutations due to aberrant somatic hypermutation affecting IRF8, which can be coding or non-coding.


B-cell lymphoma stage III

description: Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


name: Recurrent Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma

description: The reemergence of primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma after a period of remission.


name: Anaplastic Large Cell Lymphoma, Giant Cell Rich Subtype

description: An anaplastic large cell lymphoma characterized by the presence of numerous giant cells.


Cutaneous Mantle Cell Lymphoma

description: Mantle cell lymphoma that affects the skin.


name: Ann Arbor Stage II Grade 2 Follicular Lymphoma

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


name: Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

description: The reemergence of diffuse large B-cell lymphoma, not otherwise specified after a period of remission.


Recurrent T Lymphoblastic Lymphoma

description: The reemergence of T-lymphoblastic lymphoma after a period of remission.


name: Centroblastic Lymphoma Post-Transplant Lymphoproliferative Disorder

description: A centroblastic lymphoma that arises in a patient with a history of organ transplantation.


name: HHV-8 and EBV-Negative Primary Effusion-Based Lymphoma

description: An HHV-8 and EBV-negative primary effusion-based lymphoma that affects elderly, HIV-negative patients with history of medical conditions that result in fluid overload. The majority of cases have been reported in Japan. Most tumors exhibit centroblastic or immunoblastic morphology. The prognosis is good.


name: Refractory Transformed Mycosis Fungoides

description: Transformed mycosis fungoides that is resistant to treatment.


name: B-cell small lymphocytic lymphoma stage IV

description: Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Lacrimal System Non-Hodgkin Lymphoma

description: A non-Hodgkin lymphoma that arises from the lacrimal gland or the lacrimal drainage system. The majority of cases are of B-cell type. The most common subtypes are mucosa-associated lymphoid tissue lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.


Childhood Non-Hodgkin Lymphoma

description: Non-Hodgkin lymphoma occurring in childhood.


Stage I Non-Hodgkin Lymphoma

description: Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


name: Small Lymphocytic Lymphoma with Plasmacytoid Differentiation

description: A small lymphocytic lymphoma characterized by the presence of neoplastic lymphocytes with plasmacytoid morphology.


Intestinal T-Cell Lymphoma

description: A group of mature T-cell and NK-cell non-Hodgkin lymphomas that includes enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, and intestinal T-cell lymphoma, not otherwise specified. Most of these lymphomas arise from the small intestine and a minority from the large intestine or stomach.


name: Head and Neck Diffuse Large B-Cell Lymphoma

description: A diffuse large B-cell lymphoma that arises from the head and neck region. It affects both lymph nodes and extranodal sites. The most frequently affected extranodal site is the Waldeyer ring, particularly the palatine tonsil.


Duodenal-type follicular lymphoma

description: A localized low-grade follicular lymphoma within the gastrointestinal tract, which is distinct from other gastrointestinal tract follicular lymphomas.  It has features that overlap with in situ follicular neoplasia as well as some features resembling an extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. The prognosis is excellent.


name: Lymphoplasmacytoid lymphoma/immunocytoma stage IV


Oropharyngeal Non-Hodgkin Lymphoma

description: A non-Hodgkin lymphoma that arises from the oropharynx.


name: Stage I Indolent Adult Non-Hodgkin Lymphoma


Mantle cell lymphoma recurrent

description: The reemergence of a mantle cell lymphoma after a period of remission.


name: Lugano Classification Stage II Bulky Adult Non-Hodgkin Lymphoma AJCC v8

description: Stage II Bulky: Stage II with disease bulk. (from AJCC 8th Ed.)


name: Lymphomatous Adult T-Cell Leukemia/Lymphoma

description: An adult T-cell leukemia/lymphoma characterized by generalized lymphadenopathy without peripheral blood involvement.  Most patients have advanced disease, however hypercalcemia is not frequently present.


name: Pleomorphic Variant Mantle Cell Lymphoma

description: An aggressive mantle cell lymphoma characterized by the presence of pleomorphic neoplastic B-lymphocytes.


Burkitt's lymphoma of spleen

description: Burkitt lymphoma that involves the spleen.


name: Stage IV Childhood Non-Hodgkin Lymphoma by Toronto Guidelines v2

description: Initial CNS and/or bone marrow involvement. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Major Salivary Gland Non-Hodgkin Lymphoma

description: A non-Hodgkin lymphoma that arises from the parotid gland, submandibular gland, or sublingual gland.  Representative examples include mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma.


name: Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma

description: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (from PDQ)


name: Lymphoplasmacytoid lymphoma/immunocytoma stage II

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


name: Recurrent NK-Cell Lymphoma, Unclassifiable

description: The reemergence of NK-cell lymphoma, unclassifiable after a period of remission.


name: Diffuse large B-cell lymphoma, unclassifiable, NOS

description: A biologic subset of diffuse large B-cell lymphomas (DLBCL) that do not overexpress the genes whose overexpression characterizes the germinal center B-cell-like and activated B-cell-like DLBCL.  Morphologically, these lymphomas are either immunoblastic or centroblastic.  Patients with this type of diffuse large B-cell lymphoma are reported to have a less favorable outcome, similar to those with an activated B-cell-like gene expression profile.


name: Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type

description: The reemergence of follicular helper T-cell lymphoma, follicular-type after a period of remission.


name: Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8

description: Stage IVA2 includes: T1-4, N3, M0, B0-2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)


mycosis fungoides variant

description: A header term that includes the rare following variants of mycosis fungoides: folliculotropic mycosis fungoides, granulomatous slack skin disease, and pagetoid reticulosis.


Primary Bone Non-Hodgkin Lymphoma

description: A non-Hodgkin lymphoma that arises from the bone, without lymph node or other extranodal involvement.  The femur, spine, and pelvic bones are the most frequently affected areas.  The majority of cases are diffuse large B-cell lymphomas.  Most patients present with pain in the affected area.  Systemic symptoms are rare.


name: Recurrent Primary Vitreoretinal Non-Hodgkin Lymphoma

description: The reemergence of primary vitreoretinal non-Hodgkin lymphoma after a period of remission.


name: Stage I Mycosis Fungoides and Sezary Syndrome AJCC v8

description: Stage I includes: IA (T1, N0, M0, B0,1); IB (T2, N0, M0, B0,1). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)


name: Methotrexate-Associated Peripheral T-Cell Lymphoma

description: A peripheral T-cell lymphoma that develops in patients who are immunosuppressed with methotrexate.


name: Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

description: Diffuse large B-cell lymphoma, not otherwise specified that is resistant to treatment.


Refractory Lymphoblastic Lymphoma

description: Lymphoblastic lymphoma that is resistant to treatment.


name: Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma


Refractory Grade 3b Follicular Lymphoma

description: Grade 3b follicular lymphoma that is resistant to treatment.


Stage IV Adult Lymphoblastic Lymphoma

description: Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


name: Small Intestinal Monomorphic Epitheliotropic T-Cell Lymphoma

description: A monomorphic epitheliotropic intestinal T-cell lymphoma arising from the small intestine. It is characterized by the presence of a monomorphic cellular infiltrate of small to medium-sized T-lymphocytes that are cytotoxic and express CD56. It is not associated with celiac disease.


Methotrexate-Related Burkitt Lymphoma

description: A Burkitt lymphoma that develops in patients who are immunosuppressed with methotrexate.


name: Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma


name: Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8

description: Stage II includes: IIA (T1,2, N1,2, M0, B0,1); IIB (T3, N0-2, M0, B0,1). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)


name: Recurrent Extranodal Diffuse Large B-cell Lymphoma

description: The reemergence of extranodal diffuse large B-cell lymphoma after a period of remission.


name: Nodal marginal zone B-cell lymphoma stage IV


Cutaneous Burkitt Lymphoma

description: Burkitt lymphoma that affects the skin.


large B-cell diffuse lymphoma of heart

description: A diffuse large B-cell lymphoma that arises from the heart.


name: large B-cell diffuse lymphoma of accessory sinus

description: A non-Hodgkin lymphoma that arises from the paranasal sinus and is characterized by the presence of a diffuse malignant infiltrate composed of large B-lymphocytes.


name: Ann Arbor Stage III Grade 2 Follicular Lymphoma

description: Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


name: Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8

description: Stage IIA includes:  T1-2, N1,2, M0, B0,1. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)


Intestinal T-cell lymphoma stage II

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Digestive System Non-Hodgkin Lymphoma

description: A non-Hodgkin lymphoma that arises from any part of the digestive system, with the bulk of the disease localized to that site.


name: Ann Arbor Stage II Contiguous Adult Lymphoblastic Lymphoma

description: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (from PDQ)


name: Non-Hodgkin's lymphoma transformed recurrent

description: The reemergence of non-Hodgkin lymphoma transformed after a period of remission.


name: Recurrent Anaplastic Large Cell Lymphoma

description: The reemergence of anaplastic large cell lymphoma after a period of remission.


Marginal zone lymphoma stage II

description: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (PDQ)


name: Esophageal Diffuse Large B-Cell Lymphoma

description: An extranodal diffuse large B-cell lymphoma that arises from the esophagus with the bulk of the mass located in the esophagus.


name: Angioimmunoblastic T-cell lymphoma refractory

description: Follicular helper T-cell lymphoma, angioimmunoblastic-type that is resistant to treatment.


name: Refractory Indolent Adult Non-Hodgkin Lymphoma

description: Indolent adult non-Hodgkin lymphoma that is resistant to treatment.


Childhood Lymphoblastic Lymphoma

description: A lymphoblastic lymphoma occurring in children.


description: A follicular lymphoma that develops in patients who are immunosuppressed with methotrexate.


name: Mantle Cell Lymphoma with CCND2 Rearrangement

description: Mantle cell lymphoma characterized by the presence of CCND2 gene rearrangement. A small number of cases express this gene rearrangement and not CCND1 gene rearrangement.


name: Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements

description: The reemergence of high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements after a period of remission.


name: Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8

description: Stage IVB includes: T1-4, N0-3, M1, B0-2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M1: Visceral involvement (must have pathology confirmation and organ involved should be specified). B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)


name: Advanced Unfavorable Non-Hodgkin Lymphoma

description: A clinical stage II or IV non-Hodgkin lymphoma with at least four of the following risk factors: albumin level less than 4.0 g/dl, hemoglobin level of less than 10.5 g/dl, male sex, forty-five years of age or older, stage IV disease, white cell count of at least 15,000 per cubic millimeter, absolute lymphocytic count of less than 600 per cubic millimeter or a lymphocytic count of less than 8% of the total white cell count.


name: Recurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements

description: The reemergence of high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements after a period of remission.


name: Cutaneous Adult T-Cell Leukemia/Lymphoma

description: Adult T-cell leukemia/lymphoma affecting the skin.


Recurrent Plasmablastic Lymphoma

description: The reemergence of plasmablastic lymphoma after a period of remission.


name: Stage I Childhood Anaplastic Large Cell Lymphoma

description: Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


name: Endometrial Mucosa-Associated Lymphoid Tissue Lymphoma

description: A rare extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue affecting the endometrium.


NK-Cell Lymphoma, Unclassifiable

description: A very rare NK-cell lymphoma with pathologic and clinical features posing difficulty in its exact diagnosis and classification.


name: Central Nervous System Anaplastic Large Cell Lymphoma, ALK-Positive

description: An anaplastic large cell lymphoma, ALK-positive, arising from the central nervous system.


name: large B-cell diffuse lymphoma of nasal cavity

description: A non-Hodgkin lymphoma that arises from the nasal cavity and is characterized by the presence of a diffuse malignant infiltrate composed of large B-lymphocytes.


name: St. Jude Stage IV Childhood Non-Hodgkin Lymphoma AJCC v8

description: Stage IV: Any tumor, with initial CNS and/or bone marrow involvement. (from AJCC 8th Ed.)


name: St. Jude Childhood Non-Hodgkin Lymphoma by AJCC v8 Stage

description: A staging system for childhood non-Hodgkin Lymphomas based on the St. Jude Children's Research Hospital staging system. The Ann Arbor staging system has been found to be inappropriate for staging of the non-Hodgkin lymphomas of childhood. The St. Jude staging system has been widely accepted for more than three decades and remains the recommended staging system for childhood non-Hodgkin lymphomas. (from AJCC 8th Ed.)


Marginal zone lymphoma stage IV

description: Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


name: Recurrent Adult Grade III Lymphomatoid Granulomatosis

description: The reemergence of grade III lymphomatoid granulomatosis in adulthood after a period of remission.


mediastinal gray zone lymphoma

description: A mediastinal lymphoma with molecular, morphologic, immunophenotypic, and clinical features of both mediastinal (thymic) large B-cell lymphoma and classical Hodgkin lymphoma. The identification of this group of lymphomas, along with recent gene expression profiling results (PDL2 gene expression in both mediastinal (thymic) large B-cell lymphoma tissues and Hodgkin lymphoma cell lines), further supports the hypothesis that mediastinal (thymic) large B-cell lymphomas and classical Hodgkin lymphomas are related entities.


name: Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

description: The reemergence of diffuse large B-cell lymphoma that resulted from the transformation of indolent B-cell non-Hodgkin lymphoma, after a period of remission.


name: Ann Arbor Stage III Nodular Lymphocyte Predominant B-Cell Lymphoma

description: Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


name: Refractory Extranodal Diffuse Large B-cell Lymphoma

description: Extranodal diffuse large B-cell lymphoma that is resistant to treatment.


name: Ann Arbor Stage II Childhood Non-Hodgkin Lymphoma

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).